Background: Recent clinical studies demonstrate that SGLT2 (sodium-glucose cotransporter
2) inhibitors ameliorate heart failure (HF). The present study was conducted to assess the …

Background: The sympathetic nervous system (SNS) regulates glucose metabolism in
various organs including the kidneys. The sodium glucose cotransporter 2 (SGLT2) …

Abstract Purpose of Review This review aims to summarize the renal effects of sodium-
glucose transporter-2 (SGLT-2) inhibitors and their potential implications in heart failure …

Sodium glucose cotransporter 2 (SGLT2) inhibitors exert marked effects to prevent and treat
both heart failure and renal disease in people with type 2 diabetes. Recent data from the …

Purpose This study investigates the possible effect and central mechanism of novel
antidiabetic medication sodium glucose transporter-2 (SGLT-2i) on the cardiovascular …

This review focuses on the pathogenic role of sodium glucose cotransporter (SGLT)-2 in the
development of renal dysfunction and heart failure in patients with diabetes, by emphasizing …

Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …

Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose
cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic …

Even in the presence of excess glucose, the proximal renal tubules continue to resorb more
glucose. Sodium glucose cotransporter 2 (SGLT2) inhibitors are drugs that control this …

Heart failure (HF) remains the leading cause of morbidity and death in the western world,
and new therapeutic modalities are urgently needed to improve the lifespan and quality of …